GENinCode PLC Grant of Share Options and PDMR dealing (1613M)
17 September 2021 - 7:38PM
UK Regulatory
TIDMGENI
RNS Number : 1613M
GENinCode PLC
17 September 2021
17 September 2021
GENinCode Plc
("GENinCode" or the "Company")
Grant of Share Options and PDMR dealing
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease
company focused on predictive genetics for the prevention of
cardiovascular disease, announces today that the Remuneration
Committee has recommended, and the Board has approved, to issue
options over a total of 572,000 ordinary shares of GBP0.01 each in
the capital of the Company ("Share Options").
The Share Options have been issued in line with the Company's
existing share option plan to Paul Foulger, a director of the
Company. The Share Options have been issued in addition to the
existing options over ordinary shares granted to Paul Foulger on 15
April 2021 and combined, the number of ordinary shares held under
option by Paul Foulger is 1,144,000, representing 1.19% of the
existing issued ordinary share capital of the Company.
The Share Options are exercisable once the average market value
of the Company's shares for a period of 30 consecutive dealing days
following the date of the issue of the Share Options first exceeds
two times the exercise price of GBP0.44.
Contacts:
GENinCode plc www.genincode.com
Matthew Walls, CEO Via Walbrook PR
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Tel: +44 (0)20 7710 7600
Joint Broker)
Alex Price / Ben Maddison / Richard
Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode @walbrookpr.com
Anna Dunphy / Paul McManus / Louis
Ashe-Jepson
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment,
prediction and prevention of cardiovascular disease ("CVD"). CVD is
the leading cause of death worldwide accounting for approximately
18 million deaths annually. The Company's products and technology
have been developed with the aim of predicting the onset of CVD and
providing a personalised treatment pathway for patient management.
Its products have been the subject of clinical studies on over
75,000 patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the
assets, intellectual property and know-how of the Ferrer inCode and
Gendiag.exe businesses, which were then part of Grupo Ferrer
Internacional S.A., a large Spanish multinational private
pharmaceutical and healthcare company. The technology and products
acquired included Cardio inCode(R), Lipid inCode(R), Thrombo
inCode(R) and Sudd inCode(R). The Directors believe that
approximately EUR50 million has been invested in the research and
development of these products since 2007. The Company has begun to
commercialise these products in Europe and is now targeting the UK
and US.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
DIRECTOR/PDMR SHAREHOLDING
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Paul Foulger
------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status CFO
------------------ ---------------------------------------------------
b) Initial Initial Notification
notification/
Amendment
------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name GENinCode Plc
------------------ ---------------------------------------------------
b) LEI 213800UX6TE7K65O2892
------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description Ordinary Shares of GBP0.01p
of the
financial
instrument,
type of GB00BL97B504
instrument
Identification
code
------------------ ---------------------------------------------------
b) Nature Grant of conditional shares in the Company's Share
of the Option Scheme
transaction
------------------ ---------------------------------------------------
c) Price(s) Exercise Volume
and volume(s) Price
GBP0.44 572,000
--------
------------------ ---------------------------------------------------
d) Aggregated
information
- Aggregated N/A - single transaction
volume
- Price
------------------ ---------------------------------------------------
e) Date of 17 September 2021
the transaction
------------------ ---------------------------------------------------
f) Place Outside a trading venue
of the
transaction
------------------ ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSFLSUWEFSEDU
(END) Dow Jones Newswires
September 17, 2021 05:38 ET (09:38 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2023 to Apr 2024